Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.

MLA

Schaefer, Paul L., et al. “Randomized Phase II Study of Daily versus Continuous-Infusion Schedules of Topotecan in the Treatment of Extensive-Stage Small Cell Lung Cancers.” American Journal of Clinical Oncology, vol. 26, no. 3, June 2003, pp. 236–40. EBSCOhost, https://doi.org/10.1097/01.COC.0000018038.28645.46.

APA

Schaefer, P. L., Marks, R. S., Mahoney, M. R., Sloan, J. A., Bauman, M. D., Tazelaar, H. D., Kugler, J. W., Mailliard, J. A., Ebbert, L. P., & Wiesenfeld, M. (2003). Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. American Journal of Clinical Oncology, 26(3), 236–240. https://doi.org/10.1097/01.COC.0000018038.28645.46

Chicago

Schaefer, Paul L, Randolph S Marks, Michelle R Mahoney, Jeff A Sloan, Mitchell D Bauman, Henry D Tazelaar, John W Kugler, James A Mailliard, Larry P Ebbert, and Martin Wiesenfeld. 2003. “Randomized Phase II Study of Daily versus Continuous-Infusion Schedules of Topotecan in the Treatment of Extensive-Stage Small Cell Lung Cancers.” American Journal of Clinical Oncology 26 (3): 236–40. doi:10.1097/01.COC.0000018038.28645.46.